Formation Bio Forms $600 Million Drug Development Fund

Formation Bio formed a drug development fund with $600 million in capital commitments, the company announced in a press release. The fund will finance the acquisition and development of 10 to 15 clinical stage drug programs over the next three to five years.

Formation Bio acquires or licenses Phase 1 and Phase 2 programs, then uses its AI systems and clinical operations to advance them. It targets major clinical milestones within two to four years of acquiring each program.

Each program financed by the fund will operate through a separate corporate entity while using Formation Bio's development organization. Formation Bio will serve as the fund's general partner through a wholly owned subsidiary and has committed its own capital alongside research foundations, institutional endowments, hospitals and philanthropic organizations.